Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Relationship between COX-2 specific inhibitors and hypertension.

Solomon DH, Schneeweiss S, Levin R, Avorn J.

Hypertension. 2004 Aug;44(2):140-5. Epub 2004 Jun 28.

2.

Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor.

Whelton A, Maurath CJ, Verburg KM, Geis GS.

Am J Ther. 2000 May;7(3):159-75. Review. Erratum in: Am J Ther 2000 Sep;7(5):341.

PMID:
11317165
3.

Are rofecoxib and celecoxib safer NSAIDS?

[No authors listed]

Drug Ther Bull. 2000 Nov;38(11):81-6. Review.

PMID:
11138599
4.

The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.

Spiegel BM, Targownik L, Dulai GS, Gralnek IM.

Ann Intern Med. 2003 May 20;138(10):795-806. Review.

PMID:
12755551
5.

[A critical evaluation of side effect data on COX-2 inhibitors].

Pomp E.

Tidsskr Nor Laegeforen. 2002 Feb 20;122(5):476-80. Review. Norwegian.

PMID:
11961974
6.

Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs.

Phelan KM, Mosholder AD, Lu S.

J Clin Psychiatry. 2003 Nov;64(11):1328-34. Review.

PMID:
14658947
7.

Cardiovascular and renal effects of COX-2-specific inhibitors: recent insights and evolving clinical implications.

Epstein M.

Am J Ther. 2001 Mar-Apr;8(2):81-3. Review. No abstract available.

PMID:
11304661
8.

Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.

Moore PA, Hersh EV.

J Am Dent Assoc. 2001 Apr;132(4):451-6. Review.

PMID:
11315375
9.

Renal failure associated with the use of celecoxib and rofecoxib.

Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J.

Drug Saf. 2002;25(7):537-44. Review.

PMID:
12093311
11.

Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol).

Graham GG, Graham RI, Day RO.

Curr Pharm Des. 2002;8(12):1063-75. Review.

PMID:
11945151
13.

Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?

Tegeder I, Geisslinger G.

Naunyn Schmiedebergs Arch Pharmacol. 2006 Apr;373(1):1-17. Epub 2006 Apr 4. Review.

PMID:
16586083

Supplemental Content

Support Center